Comparative Pharmacology
Head-to-head clinical analysis: PERGONAL versus REPRONEX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PERGONAL versus REPRONEX.
PERGONAL vs REPRONEX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Pergonal (menotropins) is a purified preparation of gonadotropins (follicle-stimulating hormone, FSH, and luteinizing hormone, LH) extracted from postmenopausal urine. It stimulates ovarian follicular growth and maturation in women and spermatogenesis in men by acting on specific gonadal receptors.
REPRONEX (urofollitropin) is a purified preparation of follicle-stimulating hormone (FSH) that stimulates ovarian follicular growth in women who do not have primary ovarian failure. It acts by binding to FSH receptors on granulosa cells, increasing cAMP and promoting follicular development and estrogen synthesis.
Intramuscular administration: 75 IU daily for 7-12 days, then 5,000-10,000 IU hCG 24 hours after last dose.
Men: 1000-2500 IU subcutaneously 3 times weekly for 6-12 months. Women: 75-300 IU subcutaneously or intramuscularly daily for 7-12 days.
None Documented
None Documented
Terminal elimination half-life approximately 24-36 hours; clinical context: supports daily dosing in ovulation induction protocols.
Terminal elimination half-life: 24-30 hours (menotropins); clinically, it supports daily dosing during ovarian stimulation
Primarily renal: 70-80% as unchanged drug and metabolites within 24 hours; biliary/fecal excretion accounts for <5%.
Renal (approximately 80% as parent drug and metabolites); biliary/fecal (<5%)
Category C
Category C
Gonadotropin
Gonadotropin